Surmodics, Inc. (NASDAQ:SRDX) CFO Timothy J. Arens Sells 7,009 Shares

Surmodics, Inc. (NASDAQ:SRDX) CFO Timothy J. Arens sold 7,009 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now owns 70,350 shares in the company, valued at $2,774,604. The trade was a 9.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Surmodics Stock Performance

NASDAQ:SRDX opened at $39.54 on Friday. Surmodics, Inc. has a twelve month low of $25.17 and a twelve month high of $42.44. The stock’s 50 day moving average price is $38.51 and its two-hundred day moving average price is $39.58. The company has a quick ratio of 3.22, a current ratio of 3.96 and a debt-to-equity ratio of 0.25.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.14. The firm had revenue of $33.23 million for the quarter, compared to analyst estimates of $30.69 million. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%. Analysts predict that Surmodics, Inc. will post 0.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday, November 7th. StockNews.com assumed coverage on Surmodics in a research note on Saturday, November 23rd. They issued a “hold” rating on the stock. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $50.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Quest Partners LLC increased its holdings in shares of Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after acquiring an additional 1,071 shares during the last quarter. Longfellow Investment Management Co. LLC bought a new position in Surmodics during the third quarter worth $67,000. Lazard Asset Management LLC increased its holdings in shares of Surmodics by 13.4% in the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after purchasing an additional 673 shares during the last quarter. Hardin Capital Partners LLC bought a new position in shares of Surmodics in the second quarter valued at about $206,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Surmodics during the 3rd quarter worth about $220,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).